Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Alterity Therapeutics ADR ATHE

Healthcare Biotechnology
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ATHE)

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

GlobeNewswire 8 days ago

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

GlobeNewswire November 12, 2024

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

GlobeNewswire November 6, 2024

Appendix 4C - Q1 FY25 Quarterly Cash Flow Report

GlobeNewswire October 31, 2024

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

GlobeNewswire October 14, 2024

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

GlobeNewswire October 11, 2024

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

GlobeNewswire October 2, 2024

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

GlobeNewswire September 30, 2024

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

GlobeNewswire September 23, 2024
View More News ››

Opinion & Analysis (NDAQ:ATHE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ATHE)

Alterity Therapeutics Raises Profile with Multiple Data Pres

Just In: $ATHE Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's...
whytestocks - October 2, 2024

Alterity Up on Interim Data From Advance MSA Study | Benzing

BREAKING NEWS: $ATHE Alterity Up on Interim Data From Advance MSA Study | BenzingaShares of Alterity Therapeutics (NASDAQ: ATHE) were up...
whytestocks - July 18, 2024

Alterity Therapeutics to Present New Data on ATH434 at the W

Breaking News: $ATHE Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024MELBOURNE, Australia...
whytestocks - April 10, 2024

This company will be brought out

By a major, their drugs will be valued in the 100's of billions 
Biomed4077 - July 2, 2021

RE:RE:RE:+170% on the day.

My bad didn't realise those were old posts...still wondering why the spike and retreat today
1MTFSA - February 2, 2021

RE:RE:+170% on the day.

Why did it collapse? Closed up 1.74%
1MTFSA - February 2, 2021
View more Bullboard ››

Eminent Gold Corp.

Eminent Gold Corp.

Eminent Gold Corp. is a gold exploration company focused on the exploration and discovery of gold deposits in Nevada. The ...
View More »